Severe Sickle Cell Disease clinical trials

Explore recruiting severe sickle cell disease clinical trials.

Recruiting severe sickle cell disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Sickle Cell Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Long-term Follow-up Study of Subjects with β-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)

Belgium, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype

Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease

Belgium, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease

Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease

Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Sickle Cell Disease trials by city

Severe Sickle Cell Disease in Toronto Severe Sickle Cell Disease in Vancouver Severe Sickle Cell Disease in Montreal Severe Sickle Cell Disease in Calgary Severe Sickle Cell Disease in Edmonton Severe Sickle Cell Disease in Ottawa Severe Sickle Cell Disease in Winnipeg Severe Sickle Cell Disease in Quebec City Severe Sickle Cell Disease in Hamilton Severe Sickle Cell Disease in Kitchener Severe Sickle Cell Disease in London Severe Sickle Cell Disease in Halifax Severe Sickle Cell Disease in New York Severe Sickle Cell Disease in Los Angeles Severe Sickle Cell Disease in Chicago Severe Sickle Cell Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease